TY - JOUR
T1 - Elements of visuopathy of prematurity are unified by intermittent or sustained systemic inflammation
AU - for the VICTORY Study Planning Group
AU - Dammann, Olaf
AU - Morken, Tora S.
AU - Brooks, Steven E.
AU - Chu, Alison
AU - Dammann, Christiane E.L.
AU - Hartnett, M. Elizabeth
AU - Stansfield, Brian K.
AU - Wallace, David K.
AU - Brooks, Steven E.
AU - Campbell, J. Peter
AU - Chu, Alison
AU - Chui, Ken
AU - Dammann, Christiane
AU - Dammann, Olaf
AU - Fry, Rebecca
AU - Hartnett, M. Elizabeth
AU - Morken, Tora Sund
AU - O'Shea, T. Michael
AU - Smith, Brian
AU - Stansfield, Brian K.
AU - VanderVeen, Deborah
AU - Wallace, David
N1 - Publisher Copyright:
© 2025 Elsevier Ltd
PY - 2025/11
Y1 - 2025/11
N2 - We hypothesize that the major pathologies associated with the visual system in preterm infants, retinopathy of prematurity (ROP), cerebral visual impairment (CVI), and neurodevelopmental impairment (NDI), are unified by a common etio-pathogenesis involving intermittent and/or sustained systemic inflammation (ISSI). We refer to the resulting adverse visual outcomes (AVO) as “visuopathy of prematurity” (VOP). We present the published evidence supporting an etio-pathogenic paradigm centered around ISSI that begins before birth (early phase 1), is exacerbated in the newborn period (intermediate phase 2), and culminates in adverse visual and neurodevelopmental outcomes (late phase 3).
AB - We hypothesize that the major pathologies associated with the visual system in preterm infants, retinopathy of prematurity (ROP), cerebral visual impairment (CVI), and neurodevelopmental impairment (NDI), are unified by a common etio-pathogenesis involving intermittent and/or sustained systemic inflammation (ISSI). We refer to the resulting adverse visual outcomes (AVO) as “visuopathy of prematurity” (VOP). We present the published evidence supporting an etio-pathogenic paradigm centered around ISSI that begins before birth (early phase 1), is exacerbated in the newborn period (intermediate phase 2), and culminates in adverse visual and neurodevelopmental outcomes (late phase 3).
UR - https://www.scopus.com/pages/publications/105016997589
UR - https://www.scopus.com/pages/publications/105016997589#tab=citedBy
U2 - 10.1016/j.preteyeres.2025.101392
DO - 10.1016/j.preteyeres.2025.101392
M3 - Review article
C2 - 40846266
AN - SCOPUS:105016997589
SN - 1350-9462
VL - 109
JO - Progress in Retinal and Eye Research
JF - Progress in Retinal and Eye Research
M1 - 101392
ER -